ArticleDiscover oncology2025
Clinacanthus nutans (Burm.f.) Lindau facilitates cuproptosis and ameliorates colon cancer progression by inhibiting PDE3B-mediated Apelin pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColon cancer, a prevalent malignancy occurs in the gastrointestinal tract with annually increasing incidence and mortality, and Clinacanthus nutans (Burm.f.) Lindau (CN) possesses anticancer activity in a wide spectrum of tumors. This investigation aims at illuminating potential anti-cancer properties and related mechanisms of CN against colon cancer.
methodsA BALB/c mice model of colon cancer administered CN to the experimental group was constructed, followed by transcriptome sequencing on tumor tissues and screening out cuproptosis-related differentially expressed genes (DEGs) through bioinformatics. The anti-tumor efficacy of CN was validated in HT29 and HCT116 cells co-treatment of CN and drug serum by functional assays and therapeutic effects on tumorigenicity were also evaluated in vivo. In addition, the impact of PDE3B silencing on cuproptosis was elucidated and the Apelin pathway activator, CMF-019, was applied to further verify the role of PDE3B on the Apelin pathway in CN-treated cells.
resultsCN restricted tumorigenesis of colon cancer in vivo. A total of 6 cuproptosis-related DEGs were discovered containing decreased 4 genes and elevated 2 genes in tissues from tumor mice with or without high dose CN treatment. PDE3B deficiency exerted intensified inhibitory effects of CN treatment on proliferative, migratory, and invasive capability, as well as further facilitated cuproptosis. Moreover, PDE3B deletion enhanced the suppression of CN in delaying tumorigenesis. Additionally, CN retarded the malignant phenotypes and contributed to the initiation of cuproptosis in cells via the PDE3B-mediated Apelin pathway.
conclusionOur study revealed CN delayed colon cancer by regulating PDE3B via suppression of the Apelin pathway, indicating the potential clinical relevance of CN in treating colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.